R-009-001 Implementation plans

Top priority deals

Each deal is scored using a Deal Priority Score (0-100) composed of three factors. Current deals are in advanced pipeline stages with active implementation work. Upcoming deals are next in line. The board is manually updated. Priority tiers: Very High (70+), High (55-69), Medium (40-54), Low (<40).

$$S_{\text{total}} = S_{\text{amount}} + S_{\text{LTV}} + S_{\text{stage}}$$

Deal amount score $S_{\text{amount}}$ (0-40)

$$S_{\text{amount}} = \begin{cases} 40 & \text{if amount} > \text{€200k} \\ 30 & \text{if €100k} < \text{amount} \leq \text{€200k} \\ 25 & \text{if €50k} < \text{amount} \leq \text{€100k} \\ 20 & \text{if €30k} < \text{amount} \leq \text{€50k} \\ 15 & \text{if €15k} < \text{amount} \leq \text{€30k} \\ 10 & \text{if €5k} < \text{amount} \leq \text{€15k} \\ 5 & \text{if amount} \leq \text{€5k or unknown} \end{cases}$$

Lifetime value projection $S_{\text{LTV}}$ (0-40)

$$S_{\text{LTV}} = S_{\text{revenue}} + S_{\text{employees}} + S_{\text{industry}} + S_{\text{expansion}}$$

Sub-score	Tiers
$S_{\text{revenue}}$ (0-15)	€10B+ → 15, €1B+ → 12, €50M+ → 8, €10M+ → 5, unknown → 2
$S_{\text{employees}}$ (0-10)	100k+ → 10, 10k+ → 8, 5k+ → 6, 1k+ → 4, 250+ → 2, unknown → 1
$S_{\text{industry}}$ (0-10)	Pharma → 10, Healthcare chain → 8, Insurance → 7, Government → 6, Tech platform → 5, unknown → 2
$S_{\text{expansion}}$ (0-5)	Prior deals in multiple regions → 5, Large multinational → 3, Regional → 1

Deal stage score $S_{\text{stage}}$ (0-20)

$$S_{\text{stage}} = \begin{cases} 20 & \text{Contract sent} \\ 15 & \text{Decision maker bought in} \\ 12 & \text{Presentation scheduled} \\ 10 & \text{Proposal made} \\ 8 & \text{Qualified to buy} \\ 5 & \text{Appointment scheduled / early} \end{cases}$$

Scoring breakdown per deal

Deal	$S_{\text{amount}}$	$S_{\text{rev}}$	$S_{\text{emp}}$	$S_{\text{ind}}$	$S_{\text{exp}}$	$S_{\text{LTV}}$	$S_{\text{stage}}$	$S_{\text{total}}$	Tier
US J&J Psoriasis	$40$	$12$	$8$	$10$	$5$	$35$	$15$	$\mathbf{90}$	Very High
US J&J Retrospective	$25$	$12$	$8$	$10$	$5$	$35$	$15$	$\mathbf{75}$	Very High
US J&J AD Biopsy	$25$	$12$	$8$	$10$	$5$	$35$	$10$	$\mathbf{70}$	Very High
BR Novartis HS	$20$	$12$	$8$	$10$	$5$	$35$	$15$	$\mathbf{70}$	Very High
ES NTT Data CLM	$30$	$12$	$8$	$5$	$3$	$28$	$10$	$\mathbf{68}$	High
ES Sanitas Renewal	$25$	$12$	$8$	$7$	$3$	$30$	$12$	$\mathbf{67}$	High
BR J&J Oncoderm	$15$	$12$	$8$	$10$	$5$	$35$	$15$	$\mathbf{65}$	High
CL Clínica Alemana	$20$	$15$	$6$	$8$	$1$	$30$	$10$	$\mathbf{60}$	High
IT Chiesi EB 2026	$15$	$12$	$8$	$10$	$5$	$35$	$10$	$\mathbf{60}$	High
PL LUX MED Bupa	$15$	$15$	$6$	$8$	$3$	$32$	$12$	$\mathbf{59}$	High
ES GVA Licitación	$30$	$5$	$6$	$6$	$1$	$18$	$10$	$\mathbf{58}$	High
IE Pfizer	$15$	$12$	$8$	$10$	$5$	$35$	$8$	$\mathbf{58}$	High
ES Siemens & SMS	$10$	$15$	$10$	$8$	$5$	$38$	$10$	$\mathbf{58}$	High
ES Telefónica Aragón	$10$	$12$	$8$	$5$	$3$	$28$	$18$	$\mathbf{56}$	High
PT CUF Hospitais	$10$	$12$	$6$	$8$	$1$	$27$	$18$	$\mathbf{55}$	High
ES Siemens & CUN	$5$	$15$	$10$	$8$	$5$	$38$	$8$	$\mathbf{51}$	Medium
SE Visiba Care	$15$	$8$	$2$	$5$	$3$	$18$	$15$	$\mathbf{48}$	Medium
PL Novartis Urticaria	$5$	$12$	$8$	$10$	$5$	$35$	$8$	$\mathbf{48}$	Medium
UK IQVIA Interface	$5$	$15$	$10$	$5$	$5$	$35$	$8$	$\mathbf{48}$	Medium
ES Telefónica SMS	$10$	$12$	$8$	$5$	$3$	$28$	$10$	$\mathbf{48}$	Medium
MX Novartis HS	$5$	$12$	$8$	$10$	$5$	$35$	$5$	$\mathbf{45}$	Medium
ES NTT DATA SERGAS	$5$	$12$	$8$	$5$	$3$	$28$	$8$	$\mathbf{41}$	Medium
PT Lusíadas	$5$	$12$	$6$	$8$	$1$	$27$	$5$	$\mathbf{37}$	Low
Partnership Clario	$5$	$8$	$4$	$5$	$5$	$22$	$8$	$\mathbf{35}$	Low